Leo Pharma has reported positive data from the DELTA 2 trial of delgocitinib cream in moderate to severe chronic hand eczema (CHE).

The second of two pivotal Phase III clinical trials, the DELTA 2 trial has been designed for evaluating the efficacy of twice-daily delgocitinib cream against cream vehicle for a 16-week treatment period in adult patients.

Findings showed that the trial met its primary and important secondary endpoints, which confirmed the positive results of the DELTA 1 trial.

Patients treated with delgocitinib cream showed statistically significant improvement in CHE after 16 weeks. It was also found to be well-tolerated.

The cream also provided efficacious treatment and relief in early CHE symptoms.

Further analyses will be conducted for determining the complete potential of the delgocitinib cream in moderate to severe CHE adult patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LEO Pharma Global Research & Development executive vice-president Jörg Möller said: “It is incredibly exciting to see the level of consistency that our DELTA 2 results show in line with the positive DELTA 1 results announced late last year.

“CHE is a condition that we know can have a hugely negative impact on patient quality of life, physical functioning, and ability to work.

“These results bring us one step closer towards establishing delgocitinib as a best-in-class innovative topical treatment for patients affected by this hard-to-treat disease.”

The company stated that the participants who have completed the 16-week treatment in the DELTA 1 or DELTA 2 trials are offered to roll-over to the DELTA 3 extension trial for assessing the cream’s long-term effects.

It intends to later submit the detailed data from the DELTA 2 trial for scientific presentation and publication.